Galeterone
Galeterone (TOK-001 or VN/124-1) is a novel steroidal antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of the androgens. It shows selectivity for 17,20-lyase over 17-hydroxylase.
primaryTopic
Galeterone
Galeterone (TOK-001 or VN/124-1) is a novel steroidal antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and an inhibitor of CYP17A1, an enzyme required for the biosynthesis of the androgens. It shows selectivity for 17,20-lyase over 17-hydroxylase.
has abstract
Galeterone (TOK-001 or VN/124- ...... II expansion (ARMOR2) as well.
@en
CAS number
851983-85-2
FDA UNII code
WA33E149SW
IUPAC name
17-(1H-benzimidazol-1-yl)androsta-5,16-dien-3β-ol
@en
PubChem
thumbnail
Wikipage page ID
33,202,985
Wikipage revision ID
739,284,892
ChemSpiderID
molecular weight
routes of administration
smiles
C[C@]12CC[C@@H]O
StdInChIKey
PAFKTGFSEFKSQG-PAASFTFBSA-N
hypernym
comment
Galeterone (TOK-001 or VN/124- ...... ,20-lyase over 17-hydroxylase.
@en
label
Galeterone
@en
